How it works–Participants must be over 18 and there is no upper limit to participate. This is not a vaccine. Instead, the antibodies attack the COVID-19 virus directly, binding to the COVID-19 “spike” protein. This protein is a protein on coronavirus that is essential to replication of the virus. When it is blocked, the virus cannot infect the cells of your body. If the virus does not enter your cells, it cannot replicate and dies off without causing an infection.
What is my chance of getting the antibody? 2 out of 3. Of the participants, 67 percent will get the antibody in the form of a shot, and 33 percent of participants will receive the placebo, which does not include the antibody.
Is this a late stage trial? Yes. AstraZeneca’s long-acting antibody combination will advance into late stage Phase III clinical trials with approximately 5,000 participants in and outside the U.S. The trial will evaluate the safety and efficacy of these antibodies to prevent infection for up to 12 months.
How do I get more information? If you are interested and would like more information, please fill out the contact form on this page. Filling out the form does not commit you to the study, but you will be contacted to provide more information and to answer additional questions.
Study-related care is available to participants at no cost and health insurance is not required, nor needed. Participants will be compensated, up to $875 for time and travel, if they qualify and enroll in the study.
Thanks again for all you are doing as we fight this pandemic together!